AN OPEN-LABEL, ASCENDING-DOSE, FIRST-INHUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF INTRAVENOUS INFUSIONS OF ATB200 ALONE AND ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH POMPE DISEASE

Administered By

Awarded By

Contributors

Start/End

  • April 1, 2016 - September 30, 2017